Virpax Pharmaceuticals Receives Nasdaq Panel Decision, Granted Listing Continuation with Conditions
On January 6, 2025, Virpax Pharmaceuticals, Inc. announced in a Form 8-K filing that it had received a decision from the Nasdaq Hearings Panel regarding its listing on The Nasdaq Stock Market. The Panel granted the Company’s request to continue its listing, subject to specific conditions outlined in the decision. The Nasdaq Hearings Panel’s decision […]
More Stories
US Accuses China of ‘Industrial-Scale’ AI Theft Ahead of Trump’s Visit
By Michael Zhuang The White House has issued a sharply worded memo accusing China-linked entities of systematically stealing U.S. artificial...
CDC Investigating Multi-State Salmonella Outbreak Linked to Backyard Poultry
By Jack Phillips The Centers for Disease Control and Prevention has said it is investigating an outbreak of salmonella bacterial...
US Allows Venezuela to Fund Maduro’s Defense After Court Challenge
By Tom Gantert The United States will ease sanctions on Venezuela to allow its regime to pay legal fees for...
Monsanto Weedkiller Case Could Upend Billions in Compensation
By Troy Myers and Jacob Burg Like countless homeowners, John Durnell of Missouri used a popular herbicide to keep his...
Planned Obsolescence: The Silent Sabotage of the Devices We Depend On
By Stephen Zogopoulos, USNN World News The Illusion of Progress Walk into any electronics store today and you’ll see the...
Shots Fired at White House Correspondents’ Dinner, Trump Evacuated, Suspect Detained
By Emel Akan and Sam Dorman President Donald Trump and First Lady Melania Trump were evacuated from the White House...